Novelogics Biotechnology Inc. is a pre-clinical stage biotech company based in Myrtle Beach, SC, that is dedicated to revolutionizing cancer treatment through innovative antibody immunotherapies. With a focus on safety and efficacy, Novelogics aims to address the limitations of current cancer treatments by utilizing their proprietary Interceptor approach, which targets unattached immunosuppressive proteins to enhance the cancer-killing capabilities of the immune system. Led by Co-Founder Dr. Wayne Cheney, a seasoned expert in oncology research and development, Novelogics is actively seeking investments and partnerships to advance their groundbreaking program.
With a mission to provide more effective and less harmful treatments for cancer patients, Novelogics Biotechnology Inc. is at the forefront of the rapidly growing field of oncology immunotherapy. By identifying a previously overlooked area in cancer biology, Novelogics has developed a novel antibody immunotherapy that acts as an Interceptor, intercepting immunosuppressive proteins that hinder the immune system's ability to fight cancer. As the sales of oncology immunotherapies continue to rise, Novelogics offers an exciting opportunity for investors and partners to contribute to the advancement of this groundbreaking technology and make a significant impact in the fight against cancer.
Generated from the website